Jiangsu Hengrui’s Rezvilutamide Clears NMPA Hurdle, Moves Into Phase III Prostate‑Cancer Trial
CompanyDrug

Jiangsu Hengrui’s Rezvilutamide Clears NMPA Hurdle, Moves Into Phase III Prostate‑Cancer Trial

Legend Biotech Reports $524 M CARVYKTI Sales, FDA Updates & Q3 Loss
CompanyDrug

Legend Biotech Reports $524 M CARVYKTI Sales, FDA Updates & Q3 Loss

Tonghua Dongbao Secures Dominican Republic Market Launch for Insulin Aspart
CompanyDrug

Tonghua Dongbao Secures Dominican Republic Market Launch for Insulin Aspart

BCHT Receives NMPA Approval for First Adult DTaP Vaccine Covering Pertussis, Diphtheria, and Tetanus
CompanyDrug

BCHT Receives NMPA Approval for First Adult DTaP Vaccine Covering Pertussis, Diphtheria, and Tetanus

EirGenix Secures $152 M Licensing Deal for EG1206A Breast‑Cancer Biosimilar from Sandoz
CompanyDeals

EirGenix Secures $152 M Licensing Deal for EG1206A Breast‑Cancer Biosimilar from Sandoz

Humanwell Initiates Phase 2 Trial of HW231019 Tablets for Post‑Abdominal Surgery Analgesia
CompanyDrug

Humanwell Initiates Phase 2 Trial of HW231019 Tablets for Post‑Abdominal Surgery Analgesia

Bio‑Sincerity Secures XPO1 Inhibitor Deal for BIOS‑0629, Aims at Solid‑Tumor Expansion
CompanyDeals

Bio‑Sincerity Secures XPO1 Inhibitor Deal for BIOS‑0629, Aims at Solid‑Tumor Expansion

Bayer Reports Stable Q3 2025 Sales, Highlights Strong Nubeqa and Kerendia Growth
Company

Bayer Reports Stable Q3 2025 Sales, Highlights Strong Nubeqa and Kerendia Growth

FDA Announces New ‘Plausible‑Mechanism’ Pathway to Rapid Approvals for Rare Disease Treatments
Policy / Regulatory

FDA Announces New ‘Plausible‑Mechanism’ Pathway to Rapid Approvals for Rare Disease Treatments

Complete Genomics and SOPHiA Genetics Join Forces to Deliver End‑to‑End Oncology Validation on MGI’s T1+ Sequencing Platform
CompanyDeals

Complete Genomics and SOPHiA Genetics Join Forces to Deliver End‑to‑End Oncology Validation on MGI’s T1+ Sequencing Platform

Degron Therapeutics, MSD R&D, and the Next Generation of Molecular Glue Degraders
CompanyDeals

Degron Therapeutics, MSD R&D, and the Next Generation of Molecular Glue Degraders

Adicon Holdings, Crown Bioscience, and Global Lab Services Forge New Integrated Platform for Oncology Translational Research
CompanyDeals

Adicon Holdings, Crown Bioscience, and Global Lab Services Forge New Integrated Platform for Oncology Translational Research